Funder: Pfizer Inc.
Due Dates: July 1, 2026 (Proposal submission deadline; 5:00 PM Eastern)
Funding Amounts: Total pool: $1 million; typical award: $200,000–$250,000 per project (up to 5 funded); max $250,000 per study (exceptions considered with justification).
Summary: Supports quality improvement projects to advance metastatic prostate cancer care by addressing disparities, improving provider practices, and expanding access to testing and therapies.
Key Information: U.S.-based institutions only; junior faculty encouraged; multi-institutional collaboration is prioritized.